Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
McKinsey
Medtronic
Dow
Cipla
Cerilliant
Citi
Johnson and Johnson

Generated: January 18, 2019

DrugPatentWatch Database Preview

Trastuzumab - Biologic Drug Details

« Back to Dashboard

Summary for trastuzumab
Tradenames:1
Patents:759
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for trastuzumab
Pharmacology for trastuzumab
Mechanism of ActionHER2/Neu/cerbB2 Antagonists

US Patents for trastuzumab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up Novartis AG (Basel, CH) ➤ Sign Up RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up Array BioPharma Inc. (Boulder, CO) ➤ Sign Up RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up ACADEMIA SINICA (Taipei, TW) ➤ Sign Up RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for trastuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0753 Netherlands ➤ Sign Up PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
0130035 00163 Estonia ➤ Sign Up PRODUCT NAME: TRASTUZUMABEMTANSIIN;REG NO/DATE: K(2013)8149 (LOPLIK) 19.11.2013
2016 00056 Denmark ➤ Sign Up PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530
2016 00031 Denmark ➤ Sign Up PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Dow
Teva
AstraZeneca
Baxter
US Army
Cerilliant
Deloitte
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.